Trial intelligence / Profile preview

Ponezumab in mild to moderate Alzheimer's disease

NCT00722046Phase 2

Key facts

Status
Completed
Start
Dec 2008
Primary completion
Aug 2011
Countries
6
Sponsor
Pfizer
Modality
Monoclonal Antibodies
Conditions
Alzheimer's disease (AD)
01

Overview

Phase 2, randomised, double-blind trial of ponezumab in Alzheimer's disease (AD) (6 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs), Number of Participants With Change From Baseline in Brain Magnetic Resonance Imaging (MRI) Abnormalities and 3 more. Started Dec 2008; status: completed.

02

Design

6 arms
Study design
RandomizedDouble-blind
  • PF-04360365 0.1 mg/kg

    0.1 mg/kg every 60 days

  • PF-04360365 0.5 mg/kg

    0.5 mg/kg every 60 days

  • PF-04360365 1 mg/kg

    1 mg/kg every 60 days

  • PF-04360365 3 mg/kg

    3 mg/kg every 60 days

  • PF-04360365 8.5 mg/kg

    8.5 mg/kg every 60 days

  • Placebo

    Placebo every 60 days

03

Who it enrols

Patients aged 50 or older with probable Alzheimer's disease, MMSE 16-26, and no other significant neurological or cerebrovascular conditions.

04

Endpoints

Primary

  • Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

  • Number of Participants With Change From Baseline in Brain Magnetic Resonance Imaging (MRI) Abnormalities

  • Number of Participants With Gadolinium Use in Brain Magnetic Resonance Imaging (MRI)

  • Mean Cerebrospinal Fluid (CSF) Concentration of PF-04360365

  • Mean Plasma Concentration of PF-04360365

Secondary

  • Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) Score

  • Disability Assessment for Dementia (DAD) Score

  • Mean Plasma Concentration of Amyloid Beta (Aβ1-x, Aβ1-40, Aβ1-42)

  • Mean Cerebrospinal Fluid (CSF) Concentration of Amyloid Beta (Aβ1-x, Aβ1-40, Aβ1-42)

  • Mean Cerebrospinal Fluid (CSF) Concentration of Total Tau and Phospho-tau (P-tau)

  • Number of Participants With Abnormal Cerebrospinal Fluid (CSF) Protein, Red Blood Cells (RBCs), White Blood Cells (WBCs), and Glucose Concentration

  • Number of Participants With Serum Anti-Drug Anti Body (ADA)

Beyond the preview

Go deeper on NCT00722046.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00722046.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call